Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child

    Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
  2. 2

    Industry experts predicts tough choices as NewJeans' ultimatum nears

    Industry experts predicts tough choices as NewJeans' ultimatum nears
  3. 3

    Opposition chief acquitted of instigating perjury

    Opposition chief acquitted of instigating perjury
  4. 4

    Seoul city opens emergency care centers

    Seoul city opens emergency care centers
  5. 5

    [Exclusive] Hyundai Mobis eyes closer ties with BYD

    [Exclusive] Hyundai Mobis eyes closer ties with BYD
  1. 6

    [Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance

    [Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance
  2. 7

    Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push

    Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push
  3. 8

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
  4. 9

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial

    Prosecutors seek 5-year prison term for Samsung chief in merger retrial
  5. 10

    Jung's paternity reveal exposes where Korea stands on extramarital babies

    Jung's paternity reveal exposes where Korea stands on extramarital babies
소아쌤

Bukwang Pharmaceutical attains license to sell Denmark’s anti-cancer drug

By Ahn Sung-mi

Published : June 30, 2016 - 16:14

    • Link copied

[THE INVESTOR] Bukwang Pharmaceutical ’s subsidiary Dyna Therapeutics has clinched a deal with Denmark’s Solural Pharma for its new anti-cancer drug, the company said on June 30. 

Solural Pharma Solural Pharma

Dyna Therapeutic attained the exclusive rights to develop and sell SOL-804, which is used for the treatment of castration-resistant prostate cancer, around the world. 

“Bukwang is continuously pursuing to develop new medicine and the establishment of Dyna is part of that effort,” an official of the company said. “Dyna, which specializes in developing a compatible dosage form (for drugs), is a great fit to develop SOL-804.”

By Ahn Sung-mi (sahn@heraldcorp.com)

More from Headlines